Straits Times Index
3,404.42 -6.39 (-0.19%) Nikkei
41,080.13 +167.76 (+0.41%) Hang Seng
17,564.74 -234.87 (-1.32%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
55,225.75 -2,668.62 (-4.61%) CMC Crypto 200
1,144.54 -64.15 (-5.31%)
TEVA Aug 2024 15.000 call
| Previous close | 2.1100 |
| Open | 1.7700 |
| Bid | 1.8100 |
| Ask | 1.8700 |
| Strike | 15.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.7700 - 1.7700 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Business WireTeva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
TEL AVIV, Israel, July 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Business WireNew AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
TEL AVIV, Israel, June 28, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use.
Business WireTeva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
TEL AVIV, Israel, June 25, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029.
